Health - New Ebola Vaccine Arrives
Around 11,000 doses of a new, experimental anti-Ebola vaccine have arrived in the Democratic Republic of Congo, where the world's second-worst Ebola outbreak has killed more than 2,000 people.
The DRC's Health Ministry says the Ad26-ZEBOV-GP vaccine developed by US pharmaceutical giant Johnson & Johnson will be used to protect those living outside of direct Ebola transmission zones. It will be administered only to those who want it.
It is hoped that this will complement the first vaccine rolled out to fight the outbreak, the rVSV-ZEBOV-GF manufactured by the US firm Merck Sharpe and Dohme (MSD). That jab is being used on the front lines to protect those who may have come into contact with victims of the disease.
More than 250,000 people have received the Merck anti-Ebola vaccine since the beginning of the current outbreak, the tenth outbreak to strike the DRC.